Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:2014
gptkb:FDA |
| gptkbp:chemical_formula |
C40 H63 N11 O12 S
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:contraindication |
hypersensitivity to metreleptin
|
| https://www.w3.org/2000/01/rdf-schema#label |
Myalept
|
| gptkbp:ingredients |
gptkb:metreleptin
|
| gptkbp:manufacturer |
gptkb:Amgen
|
| gptkbp:packaging |
single-use vial
|
| gptkbp:route_of_administration |
subcutaneous injection
|
| gptkbp:side_effect |
headache
nausea abdominal pain injection site reactions hypoglycemia |
| gptkbp:storage |
refrigerated
|
| gptkbp:used_for |
treatment of lipodystrophy
|
| gptkbp:weight |
883.03 g/mol
|
| gptkbp:bfsParent |
gptkb:Shire_plc
|
| gptkbp:bfsLayer |
5
|